Overall rank by patents
#25,757
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 9 technology areas, active 2020–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
The verdict
Aires holds 10 US patents across 9 technology areas, rank #25,757 of 50,000 tracked assignees.
Aires Medical Llc. has been granted 10 US utility patents between 2020 and 2023, placing Aires Medical Llc. at rank #25,757 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.9 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, Aires Medical Llc. is one of the more focused assignees in the PatentsView dataset. By volume, Aires sits between Agfa Offset BV (10 patents, rank #25,753) and Alcatel Submarine Networks (10 patents, rank #25,761) - the closest US assignees by grant volume. The composite Innovation Score of 31.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2023, with 10 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Aires Medical Llc.'s 13.9 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Aires Medical Llc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Agfa Offset BV
10 patents
Ahlstrom Corporation
10 patents
Aimmune Therapeutics, Inc.
10 patents
Airbus Corporate Jet Centre
10 patents
Aix-Marseille Universite
10 patents
Akadeum Life Sciences, Inc.
10 patents
Akoya Biosciences, Inc.
10 patents
Alcatel Submarine Networks
10 patents
Aires Medical LLC.
10 patents
What this shows Aires holds 10 patents at rank #25,757, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Aires's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
32 Top 61% higher than 39% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 2 | 20.0% |
| 2021 | 4 | 40.0% |
| 2022 | 2 | 20.0% |
| 2023 | 2 | 20.0% |
Top 9 of 9 technology areas
Overall rank by patents
#25,757
Across all tracked assignees
31.7 out of 100
How to use this portfolio
Aires's 10 grants land it in the top 61% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.